Dr. Dianzhuo (John) Wang earned his Ph.D. in Applied Physics from Harvard. His research integrated biophysics and machine learning to forecast viral variants and develop state-of-the-art models for protein design. As CSO of TwentyTwo, he leads research strategy to develop machine learning tools to prepare for biological risks.

Evan was previously at SecureBio working on desktop synthesizer security, ultraviolet PPE, and AIxBio evaluations. He finished his Bachelor’s and Master’s last year at MIT, and he’s leading TwentyTwo to work on improving security for the life sciences ecosystem.

Sophie is the technical lead for the International Screening Standards initiative, which seeks to support the harmonization and standardization of screening approaches around the world. She is a member of the International Gene Synthesis Consortium (IGSC), the OECD Synthetic Biology Working Party, Pandemic Action Network (PAN), several other international policy fora and the former French representative at ISO TC 276: Biotechnology working group.

Previously, Sophie played a critical role in the revision of the ASPR/HHS Screening Framework Guidance for providers and users of synthetic nucleic acides, namely by providing expert input on the specific challenges faced by benchtop device manufacturers, and the solutions developed by them. At the EU level, Sophie actively contributes to discussions around the EU Biotech Act and the Bioeconomy, working collaboratively with key stakeholders across the synthetic biology ecosystem. She regularly speaks at international conferences including SynBioBeta, SynbiCITE, and the OECD.

She has spent much of her career working at the interface of science, public policy, and health, building trusted relationships with governments, civil society, and the private sector. Prior to joining IBBIS, she held senior roles in international organizations, think tanks, and the private sector. She lectures on governance and emerging technologies at Sciences Po (Paris). Sophie holds post-graduate degrees from the Sorbonne Law School, Johns Hopkins School of Advanced International Studies (SAIS), and the London School of Hygiene and Tropical Medicine (LSHTM).

Piers D. Millett, Ph.D. is Executive Director of the International Biosecurity and Biosafety Initiative for Science (IBBIS). Dr. Millett is a certified biorisk management professional, with a specialization in biosecurity.

Dr. Millett was Deputy Head of the Implementation Support Unit for the Biological Weapons Convention (BWC), a treaty for which he worked for over a decade. He has consulted for the World Health Organization, supporting its integration of research and development into responses to public health emergencies and considering the health implications of advances in technology. As Vice President for Responsibility for iGEM Foundation (International Genetically Engineered Machines Competition), Dr. Millett established and ran a program strengthening the culture of responsibility and risk management with more than 350 projects each year, involving more than 6,000 young scientists and engineers from 45 countries across every inhabited continent.
Trained originally as a microbiologist, Dr. Millett has worked closely with the citizen science movement, synthetic biologists, the biotechnology industry as well as national and international policymakers and decisionmakers. He has collaborated with a range of intergovernmental organizations spanning human and animal health, humanitarian law, disarmament, security, border control, law enforcement, and weapons of mass destruction— both inside and out of the United Nations system.

He holds a Ph.D. in International Relations and Affairs, an MRes in Research Methodology, and an MA in International Politics and Security Studies—all from the University of Bradford. He has a BSc in Microbiology from the University of Leeds.